Furvent, in first-line EGFR exon 20 insertion lung cancer, reads out imminently.
ApexOnco Front Page
Recent articles
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
Studies presented at ASH show this to be true only up to a point.
The first stage of Preserve-003 shows a survival benefit in post-PD-(L)1 lung cancer – with caveats.
The company will try to get the Komzifti QTc prolongation warning removed.
On efficacy, at least, BeOne’s BTK degrader shows an edge.
Of 15 treatment-emergent adverse events, only one was deemed related to therapy.
It’s less about being fast, more about producing a better product.
